Acadia Healthcare Company, Inc. (ACHC)
| Market Cap | 2.76B +34.5% |
| Revenue (ttm) | 3.37B +4.3% |
| Net Income | -1.13B |
| EPS | -12.44 |
| Shares Out | 93.10M |
| PE Ratio | n/a |
| Forward PE | 17.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,182,120 |
| Open | 28.49 |
| Previous Close | 28.14 |
| Day's Range | 28.20 - 29.68 |
| 52-Week Range | 11.43 - 35.83 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 33.39 (+12.73%) |
| Earnings Date | Jul 28, 2026 |
About ACHC
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilities and eating disorder facilities; comprehensive treatment centers; and residential treatment centers, as well as facilities providing outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ACHC stock is "Buy." The 12-month stock price target is $33.39, which is an increase of 12.73% from the latest price.
News
Robbins LLP Notifies Acadia Healthcare (ACHC) Investors that the Lawsuit Survived Defendants' Motion to Dismiss - Contact Robbins LLP for Information
SAN DIEGO, July 31, 2026 /PRNewswire/ -- Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC) to pro...
Acadia Healthcare price target raised to $39 from $38 at Guggenheim
Guggenheim analyst Jason Cassorla raised the firm’s price target on Acadia Healthcare (ACHC) to $39 from $38 and keeps a Buy rating on the shares. After Acadia reported core EBITDA…
Acadia Healthcare price target raised to $32 from $25 at Barclays
Barclays raised the firm’s price target on Acadia Healthcare (ACHC) to $32 from $25 and keeps an Equal Weight rating on the shares post the Q2 report. The company’s “beat-and-raise”…
Acadia Healthcare price target raised to $14.50 from $13 at BofA
BofA raised the firm’s price target on Acadia Healthcare (ACHC) to $14.50 from $13 and keeps an Underperform rating on the shares. The firm attributes it raised target to raised…
Acadia Healthcare Company Earnings Call Transcript: Q2 2026
Second quarter results met or exceeded guidance, with strong free cash flow, disciplined capital deployment, and accelerated ramp-up at new facilities. Revenue was flat year-over-year but grew 2.8% after normalizing for supplemental payments. Leadership changes and operational focus are driving improved execution.
Acadia Healthcare Company Quarterly report: Q2 2026
Acadia Healthcare Company has published its Q2 2026 quarterly earnings report on July 29, 2026.
Acadia Healthcare Company Earnings release: Q2 2026
Acadia Healthcare Company released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Acadia Healthcare Company Slides: Q2 2026
Acadia Healthcare Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Acadia Healthcare’s PLGL headwind offsets DPP benefit, says Cantor Fitzgerald
Acadia Healthcare (ACHC) raised 2026 EBITDA guidance on DPP upside, but an unexpected increase in professional and general liability reserves created a near-term earnings headwind and likely pressure ...
Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2026. Second Quarte...
Acadia Healthcare (NASDAQ: ACHC) Investors: Court Denies Motion to Dismiss Paving Way for Litigation to Proceed; Contact Robbins LLP for Information About Your Rights
SAN DIEGO--(BUSINESS WIRE)---- $ACHC #Medicine--Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC)...
Acadia Healthcare price target raised to $38 from $31 at Guggenheim
Guggenheim analyst Jason Cassorla raised the firm’s price target on Acadia Healthcare (ACHC) to $38 from $31 and keeps a Buy rating on the shares. The firm updated its Q2…
Acadia Healthcare price target raised to $36 from $30 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Acadia Healthcare (ACHC) to $36 from $30 and keeps a Buy rating on the shares. The firm adjusted targets…
Acadia Healthcare price target raised to $40 from $30 at KeyBanc
KeyBanc raised the firm’s price target on Acadia Healthcare (ACHC) to $40 from $30 and keeps an Overweight rating on the shares. Healthcare utilization continued to moderate through the first…
Acadia Healthcare Announces Date for Second Quarter 2026 Earnings Release
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the ...
Acadia Healthcare price target raised to $39 from $31 at UBS
UBS raised the firm’s price target on Acadia Healthcare (ACHC) to $39 from $31 and keeps a Buy rating on the shares.
Jefferies upgrades Acadia Healthcare to Buy on belief in new management
As previously reported, Jefferies upgraded Acadia Healthcare (ACHC) to Buy from Hold with a price target of $30, up from $24.50, citing a belief that new management is well-positioned to…
Acadia Healthcare upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded Acadia Healthcare (ACHC) to Buy from Hold with a price target of $30, up from $24.50.
Acadia Healthcare price target raised to $31 from $28 at RBC Capital
RBC Capital raised the firm’s price target on Acadia Healthcare (ACHC) to $31 from $28 and keeps an Outperform rating on the shares after its Q1 earnings beat. Shares reversed…
Acadia Healthcare price target raised to $31 from $26 at Guggenheim
Guggenheim raised the firm’s price target on Acadia Healthcare (ACHC) to $31 from $26 and keeps a Buy rating on the shares, citing higher EBITDA estimates and execution “deserving of…
Acadia Healthcare upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded Acadia Healthcare (ACHC) to Strong Buy from Outperform with a price target of $39, up from $25. The company reported a solid 1Q beat and modestly raised…
Acadia Healthcare price target raised to $30 from $20 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Acadia Healthcare (ACHC) to $30 from $20 and keeps a Neutral rating on the shares. Accelerating bad debt and denial trends, though…
Acadia Healthcare price target raised to $32 from $26 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Acadia Healthcare (ACHC) to $32 from $26 and keeps a Buy rating on the shares.
Acadia Healthcare Company Earnings Call Transcript: Q1 2026
Revenue and Adjusted EBITDA exceeded guidance in Q1 2026, driven by strong acute and RTC performance. Full-year Adjusted EBITDA and EPS guidance were raised, while operational improvements and leadership changes support continued growth.
Acadia Healthcare Company Earnings release: Q1 2026
Acadia Healthcare Company released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.